A Phoenix Grows in Utah: Five Years After Rebirth, Prolexys Raises $20M to Make Rxs | GenomeWeb
What happens when you start a business, get tens of millions of dollars in funding, and discover shortly afterward that the market may have no interest in your product?
In the case of Prolexys Pharmaceuticals, it took its technology and recast the company into exactly the kind of end-market user that was supposed to be its customer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.